Steve Schonfeld’s ACELYRIN SLRN Stock Holding History

Steve Schonfeld’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-202,662	Closed	-$2.06M	–	2180
2023 Q3	$2.06M	Buy	202,662 +147,454	+267%	+$3.13M	0.02%	819
2023 Q2	$1.15M	Buy	+55,208	New	+$1.13M	0.01%	925

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Steve Schonfeld's SLRN Position: Q4 2023 in Review

Steve Schonfeld sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 202,662 shares — an estimated $2.06M sold.

Steve Schonfeld first reported a position in SLRN in Q2 2023 and held it in 2 quarters. The position peaked at $2.06M in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Steve Schonfeld reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Steve Schonfeld sold 202,662 ACELYRIN shares in Q4 2023, an estimated $2.06M.
Steve Schonfeld first reported a position in ACELYRIN in Q2 2023 and held it in 2 quarters.
Steve Schonfeld's ACELYRIN position peaked at $2.06M in Q3 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.